---
title: "Weekly Recap | Stryker -8.33%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298103535.md"
description: "Stryker fell 8.33% this week to close at $303.13, sharply underperforming the S&P 500, which rose 0.09% over the same period—a relative gap of about 8.42 percentage points. The selling was mostly one-way: Monday opened at $327.79 and closed at $323.80, Tuesday broke below $320, Wednesday and Thursday pushed further down toward $307, and Friday touched an intraday low of $302.51 before settling at $303.13. Weekly amplitude was 8."
datetime: "2026-09-05T08:21:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298103535.md)
  - [en](https://longbridge.com/en/news/298103535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298103535.md)
generator: "portal-rs"
---

# Weekly Recap | Stryker -8.33%, consensus target above spot

## The Week

Stryker fell 8.33% this week to close at $303.13, sharply underperforming the S&P 500, which rose 0.09% over the same period—a relative gap of about 8.42 percentage points. The selling was mostly one-way: Monday opened at $327.79 and closed at $323.80, Tuesday broke below $320, Wednesday and Thursday pushed further down toward $307, and Friday touched an intraday low of $302.51 before settling at $303.13. Weekly amplitude was 8.84%, leaving the stock roughly 14% below its 60-day range high of $352.49.

## Key Events

M&A and insider activity anchored the week’s news flow. On 1 September, Stryker agreed to acquire ZuriMED, a developer of rotator cuff augmentation technology; the deal was reported alongside IES Holdings’ $670 million acquisition in a wider small-cap deal wave, with some coverage framing it as part of Stryker’s more aggressive 2026 playbook amid rising cyber-attack concerns across medical technology. On 3 September, director Mary K. Brainerd disclosed a $4,120.75 purchase of common shares, described in the same day’s coverage as a fresh insider buy. Several daily notes flagged Stryker underperforming competitors, and NS Partners Ltd disclosed selling shares, though the latter carries less weight as a routine position change than the company’s own deal and insider buying.

## Analyst Ratings

Across 29 institutions covering Stryker, 15 rate it buy, 7 rate it overweight, 6 rate it hold, and 1 has no opinion, with no sell or underweight ratings. The consensus rating is buy, and the consensus target price is $382.72, about 26.26% above the current price of $303.13. Target prices range from $315.00 to $465.00, a wide gap that points to meaningful dispersion among analysts. Stryker ranks 6th within the medical devices industry, better than the industry average rank of 7.

## The Week Ahead

The macro calendar is relatively busy next week. On 8 September the US releases the NFIB Small Business Optimism Index, with a prior reading of 99.8. On 10 September, initial jobless claims, final demand PPI, core PPI, existing home sales, and wholesale sales are due. For Stryker, a schedule update on 4 September confirmed the company will participate in the 2026 Wells Fargo Healthcare Conference, which will be a moment to watch for management commentary.

## In Short

Stryker’s decline this week stood out against a flat S&P 500, and repeated underperformance versus competitors pointed to selling pressure beyond the broader market. Yet the ratings backdrop remains positive, with a consensus target well above spot and small insider buying, creating a contrast with the weak price action. The next signals to watch are management remarks at the healthcare conference and whether the macro data keep pressuring medical-device names.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [SYK.US](https://longbridge.com/en/quote/SYK.US.md)

## Related News & Research

- [Why Stryker (SYK) Is Back In The Spotlight](https://longbridge.com/en/news/300223498.md)
- [27,714 Stryker Corporation $SYK Shares Sold by Engineers Gate Manager LP](https://longbridge.com/en/news/300192925.md)
- [RBC Capital Remains a Buy on Stryker (SYK)](https://longbridge.com/en/news/300836603.md)
- [TD Cowen maintains Hold rating on Stryker, $298 price target](https://longbridge.com/en/news/299788601.md)
- [Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS](https://longbridge.com/en/news/299346954.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**